Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SUNPHARMA.NS
BuyPremium GrowerSun Pharmaceutical Industries Limited · Healthcare · India · $47.7B · Avg Vol: $35M/d
78
StockRankGet insider-trade alerts
Q
76
V
28
M
69
P/E (TTM)
37.0x
ROE
13.7%
D/E
0.1x
Dividend %
0.9%
COMPANY DESCRIPTION
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 432.8B | 477.6B | 520.4B | 582.2B | 10.4% | 601.2B | 648.3B | 726.0B | 11.7% |
| EPS (INR) | 35.30 | 39.90 | 45.60 | 47.80 | 10.6% | 50.52 | 50.31 | 59.31 | 11.4% |
| Shares | 2.4B | 2.4B | 2.4B | 2.4B | 0.0% | 2.4B | — | — | — |
| Debt | 68.9B | 32.7B | 23.6B | 46.3B | -12.4% | 46.4B | — | — | — |
| Equity | 560.0B | 636.7B | 722.2B | 835.7B | 14.3% | — | — | — | — |
| Op CF | 49.6B | 121.3B | 140.7B | 124.2B | 35.8% | 124.6B | — | — | — |
| Inv CF | -79.4B | -6.9B | -53.1B | -113.4B | — | — | — | — | — |
| Fin CF | 23.8B | -67.1B | -79.1B | -25.1B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-6.8%
SMA 50SMA 200
Close
$19.54
RSI (14)
42.3
52W High
$21.45
From 52W High
0.9%
SCORE BREAKDOWN
Quality
76
ROIC
17.9%88.3
ROE
13.7%79.7
GP/Assets
43.5%81.5
Op. Margin
23.2%86.6
FCF/Assets
8.1%81.6
Piotroski
549.3
Int. Cover
45.6x77.8
D/E Ratio
0.06x70.0
Current Ratio
2.82x52.6
Value
28
P/E (TTM)
37.0x31.4
EV/EBITDA
25.6x25.7
P/FCF
51.5x29.4
P/B
5.4x26.5
P/S
7.5x31.5
Div Yield
0.9%25.2
Momentum
69
52W High %
91%86.4
RS 6M
7%71.2
SMA 50/200
1.07x71.5
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+28%40.8
Q Growth
27%60.7
FUNDAMENTALS
Market Cap
$47.7B
P/E (Forward)
28.9x
Gross Margin
78.9%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SUNPHARMA.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SUNPHARMA.NS | Sun Pharmaceutical Industries Limited(you) | $47.7B | 78 | Buy |
| DIVISLAB.NS | Divi's Laboratories Limited | $26.8B | 73 | Buy |
| LAURUSLABS.NS | Laurus Labs Limited | $11.1B | 75 | Buy |
| ZYDUSLIFE.NS | Zydus Lifesciences Limited | $12.1B | 68 | Buy |
| CIPLA.NS | Cipla Limited | $11.8B | 68 | Buy |
| MANKIND.NS | Mankind Pharma Limited | $10.1B | 69 | Buy |
| ABBOTINDIA.NS | Abbott India Limited | $5.7B | 79 | Buy |
| AUROPHARMA.NS | Aurobindo Pharma Limited | $10.3B | 91 | Strong Buy |
| TORNTPHARM.NS | Torrent Pharmaceuticals Limited | $19.9B | 52 | Hold |
| LUPIN.NS | Lupin Limited | $10.2B | 91 | Strong Buy |
Peer medians: ROE 11.8% · P/E 42.8x · Gross margin 59.4%